Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12399777.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rituximab, a chimeric monoclonal antibody directed against CD20 of B cells, has been reported to be effective in the treatment of B-cell lymphomas and malignant and nonmalignant plasma cell-dependent diseases. We describe a 30-year-old woman with refractory pemphigus vulgaris who experienced a partial remission after treatment with rituximab.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Pemphigus